Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Gross Profit (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Gross Profit data on record, last reported at $129.2 million in Q3 2025.

  • For Q3 2025, Gross Profit rose 33.45% year-over-year to $129.2 million; the TTM value through Sep 2025 reached $433.2 million, up 15.92%, while the annual FY2024 figure was $377.3 million, 298.76% up from the prior year.
  • Gross Profit reached $129.2 million in Q3 2025 per COLL's latest filing, up from $108.4 million in the prior quarter.
  • Across five years, Gross Profit topped out at $129.2 million in Q3 2025 and bottomed at -$1.3 million in Q4 2021.
  • Average Gross Profit over 5 years is $73.6 million, with a median of $77.4 million recorded in 2023.
  • Peak YoY movement for Gross Profit: tumbled 103.01% in 2021, then soared 3835.11% in 2022.
  • A 5-year view of Gross Profit shows it stood at -$1.3 million in 2021, then skyrocketed by 3835.11% to $49.8 million in 2022, then skyrocketed by 90.06% to $94.6 million in 2023, then rose by 3.87% to $98.3 million in 2024, then soared by 31.42% to $129.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $129.2 million in Q3 2025, $108.4 million in Q2 2025, and $97.3 million in Q1 2025.